Objectif
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID underlying recombination defects, this has not yet occurred due to the higher complexities of the affected genes involved. The aim of the current proposal is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell based gene therapy. To this end we will develop novel safety assays, pre-GMP and GMP lentiviral batches and design and conduct multicenter, multinational clinical trials with input from regulatory authorities such as EMA and patient advocacy groups. The trial will be conducted with phenotypic, molecular (integration sites, therapeutic gene expression) and functional readouts and should lead to effective treatment for > 70% of all SCID patients in Europe. RECOMB forms the logical extension of highly successful previous EU consortia that have made the EU global leader in gene therapy for orphan immune diseases.
Champ scientifique
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineemergency medicinegraft versus host disease
- medical and health sciencesclinical medicinetransplantation
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
2333 ZA Leiden
Pays-Bas
Voir sur la carte
Participants (16)
75654 Paris
Voir sur la carte
WC1E 6BT London
Voir sur la carte
WC1N 3JH London
Voir sur la carte
20132 Milano
Voir sur la carte
30625 Hannover
Voir sur la carte
89081 Ulm
Voir sur la carte
50 367 Wroclaw
Voir sur la carte
NE1 7RU Newcastle Upon Tyne
Voir sur la carte
PL11 3LE Torpoint
Voir sur la carte
2333 CL Leiden
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
08035 Barcelona
Voir sur la carte
00165 Roma
Voir sur la carte
75012 Paris
Voir sur la carte
52621 Ramat Gan
Voir sur la carte
80539 MUNCHEN
Voir sur la carte
69120 Heidelberg
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.